NextCure (NASDAQ:NXTC) Releases Quarterly Earnings Results, Misses Estimates By $0.39 EPS

NextCure (NASDAQ:NXTC) posted its quarterly earnings results on Tuesday. The company reported ($1.29) EPS for the quarter, missing the consensus estimate of ($0.90) by ($0.39), FiscalAI reports.

NextCure Price Performance

Shares of NextCure stock traded down $0.29 during trading on Tuesday, hitting $5.98. 81,522 shares of the stock were exchanged, compared to its average volume of 673,259. The stock has a market cap of $21.59 million, a price-to-earnings ratio of -0.69 and a beta of 1.22. The firm’s 50-day moving average price is $6.06 and its 200 day moving average price is $7.67. NextCure has a 12-month low of $1.55 and a 12-month high of $15.74.

Wall Street Analyst Weigh In

A number of equities research analysts recently issued reports on NXTC shares. HC Wainwright reissued a “buy” rating on shares of NextCure in a report on Thursday, August 13th. Wall Street Zen raised shares of NextCure from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Finally, Weiss Ratings lowered shares of NextCure from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, October 26th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, NextCure currently has an average rating of “Hold” and a consensus target price of $20.00.

Insiders Place Their Bets

In other NextCure news, major shareholder Adar1 Capital Management, Llc purchased 5,626 shares of the business’s stock in a transaction on Friday, October 23rd. The shares were bought at an average cost of $4.83 per share, for a total transaction of $27,173.58. Following the completion of the purchase, the insider directly owned 728,045 shares in the company, valued at approximately $3,516,457.35. This represents a 0.78% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders acquired 15,537 shares of company stock valued at $77,603 in the last 90 days. 11.90% of the stock is owned by company insiders.

NextCure Company Profile

NextCure, Inc. (NASDAQ: NXTC) is a clinical-stage biotechnology company focused on developing immunomedicines for the treatment of cancer. The company’s research is aimed at identifying and targeting biological mechanisms that suppress the immune system’s ability to recognize and attack tumor cells. NextCure’s product candidates have included NC318, an antibody designed to target Siglec-6, and NC410, a fusion protein intended to block the LAIR-1 immune-suppressive pathway. These programs have been evaluated in early-stage clinical studies involving patients with advanced solid tumors, with the goal of developing treatments that may restore or enhance anti-tumor immune responses.